Date: 2016-12-15
Type of information: Product acquisition
Compound: TG3003, now ELB 041 (anti-CD115 antibody)
Company: Elsalys Biotech (France) Transgene (France)
Therapeutic area: Cancer - Oncology
Type agreement: product acquisition
Action mechanism: monoclonal antibody. TG3003, now ELB 041, is an immunomodulatory anti-CD115 monoclonal targeting M2-macrophage polarization in the tumor microenvironment. M-CSF is a cytokine essential to the survival and differentiation of myeloid lineage cells (monocytes, macrophages, dendritic cells…). The M-CSF receptor (M-CSF-R or CD115) therefore proves to be a promising therapeutic target to modulate the activity of some of these cells, notably those implicated in the tumoral progression as the Tumor Associated Macrophages (TAM).
The antibody down-modulates CD115 signaling and inhibits the secretion of MCP-1/CCL2 by differentiating macrophages. It also decreases their IL-6 production.
Disease:
Details: * On December 15, 2016, Elsalys Biotech announced the acquisition of development and marketing rights for TG3003 anti-CD115 (as of now ELB041) from Transgene. The first studies conducted by Transgene with the anti-CD115 ELB041 demonstrate the latter could counter this deleterious effect: it lifts the immunosuppression mediated by the M2 macrophages (Immune Checkpoint Inhibitor or ICI) while restoring the ability of the immune system to destroy the tumor cells (Antibody-Dependent Cell-mediated Cytotoxicity or ADCC). Elsalys Biotech will now initiate a preclinical study targeting proof-of-concept in immuno-oncology
Financial terms: In exchange for the license granted to Elsalys Biotech (along with all related sublicensing rights), Transgene will be eligible to receive milestone payments until the medicinal product is registered and will receive royalties based on future sales.
Latest news:
